论文部分内容阅读
目的:探讨新辅助化疗对于ⅢA-N_2期NSCLC的降期作用及疗效。方法:回顾性分析2004年1月至2008年12月期间26例接受新辅助和44例术后辅助化疗的ⅢA-N_2期NSCLC患者的临床资料。结果:新辅助化疗组R_0切除22例,10例降期至_N1,6例降期至N0,R_0切除率为84.6%;辅助化疗组R_0切除率为54.55%,两组差异有统计学意义。3年生存率新辅助化疗组为73%,辅助化疗组为49%,两组差异有统计学意义(P<0.05)。结论:新辅助化疗可明显改善ⅢA-N_2期患者手术效果,降低N分期,提高患者生存,同时并未增加手术并发症和患者死亡。
Objective: To investigate the effect and effect of neoadjuvant chemotherapy on stage ⅡA-N_2 NSCLC. Methods: The clinical data of 26 patients with stage ⅢA-N_2 NSCLC receiving neoadjuvant and 44 cases of postoperative adjuvant chemotherapy between January 2004 and December 2008 were retrospectively analyzed. Results: Neoadjuvant chemotherapy group R0 resection in 22 cases, 10 cases down to _N1,6 cases down to N0, R_0 resection rate was 84.6%; adjuvant chemotherapy group R_0 resection rate was 54.55%, the difference between the two groups was statistically significant . The 3-year survival rate was 73% in the neoadjuvant chemotherapy group and 49% in the adjuvant chemotherapy group, with significant difference between the two groups (P <0.05). Conclusion: Neoadjuvant chemotherapy can significantly improve the surgical outcome in patients with stage ⅢA-N_2, reduce the N stage and improve the survival of patients without increasing the complications of surgery and the death of patients.